Search results for "Diphosphonates"

showing 10 items of 124 documents

Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain.

2014

Background: Osteonecrosis of the jaw (ONJ) is a destructive bone process in patients undergoing bisphosphonate therapy and it is modulated by local and systemic factors. The purpose of this article is to determine the prevalence of ONJ in patients who have undergone intravenous bisphosphonate therapy, and relate the risk factors described to establish a protocol to reduce the risk of developing ONJ. Material and Methods: We performed a retrospective study on 194 patients treated with IV bisphosponates, analyzing clinical and pathological variables. Results: The prevalence of ONJ was 12.9 %. The most remarkable complication was pain, which was reported by 80% of patients. The average age of …

AdultMalemedicine.medical_specialtyOdontologíaOral hygieneRisk FactorsmedicinePrevalenceHumansRisk factorGeneral DentistryPathologicalAgedRetrospective StudiesAged 80 and overBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchRetrospective cohort studyMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASEtiologySurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawComplicationbusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution

2012

Objective: To assess the clinical features of exodontias performed in cancer patients who have been receiving intravenous bisphosphonates (BPs). Study Design: This is a retrospective cohort study using a sample of 20 patients receiving BPs who had 62 teeth extracted. An univariate analysis was applied to calculate socket healing time (HT), comparing among exodontias performed according to cause, such as periodontal disease or caries, type of BP, and use of corticosteroid. In order to analyze the influence of each variable on HT, multiple statistical analyses were performed through logistic multiple regression. Results: From the 62 tooth extractions performed, 5 exodontias had evolved to 4 s…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentDentistryOdontologíaCohort StudiesmedicineHumansTooth SocketGeneral DentistryDental alveolusAgedRetrospective StudiesAged 80 and overUnivariate analysisWound HealingDiphosphonatesbusiness.industryCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASCorticosteroidSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsbusinessOsteonecrosis of the jawCohort study
researchProduct

Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd: YAG low-level laser …

2013

Objective: Trauma during dental surgery is a predisposing factor for bisphosphonates (BP)-related osteonecrosis of the jaws (BRONJ). However, about 40% of cases of BRONJ are not related to dental invasive procedures, being probably associated to endodontic or periodontal infections. Extraction of non-treatable teeth is considered a reliable choice, to improve symptoms and to reduce the risk of BRONJ. Here we report our experience of tooth extractions in patients under oral or intravenous BP therapy. Study Design: Two-hundred and seventeen patients (38 males, 179 females; mean age 68.72 ± 11.26 years, range 30 to 83 years) under BP therapy received 589 tooth extractions at the Unit of Oral M…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentOsteoporosisAntibioticsDentistryOdontologíaLasers Solid-StatePostoperative ComplicationsClinical ProtocolsmedicineHumansLow-Level Light TherapyDental CareGeneral DentistryMultiple myelomaLow level laser therapyAgedAged 80 and overBisphosphonate-associated osteonecrosis of the jawDiphosphonatesbusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgerystomatognathic diseasesOtorhinolaryngologyRheumatoid arthritisDental surgeryTooth ExtractionUNESCO::CIENCIAS MÉDICASResearch-ArticleBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryOral SurgerybusinessOral medicine
researchProduct

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

2006

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of…

Aged 80 and overMaleBone Density Conservation AgentsDiphosphonatesZoledronic > acidImidazolesProstatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedProteinaseZoledronic AcidCathepsin BMatrix > metalloproteinase-9Matrix Metalloproteinase 9Matrix metalloproteinase-2Bone metastasiBisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase-2; Matrix > metalloproteinase-9; Proteinases; Urokinase-type plasminogen activator; Zoledronic > acidHumansMatrix Metalloproteinase 2BisphosphonateFemaleUrokinase-type plasminogen activatorAged
researchProduct

Novel formulations of oral bisphosphonates in the treatment of osteoporosis

2022

AbstractOral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still mainta…

AgingDiphosphonatesAlendronateAlendronate/adverse effects610 Medicine & healthRisedronic Acid/therapeutic useDiphosphonates/adverse effectsFractures BoneHumansOsteoporosisAlendronate Bisphosphonates Fragility fracture Osteoporosis Risedronate TherapyGeriatrics and Gerontology610 Medizin und GesundheitBoneFracturesRisedronic AcidOsteoporosis/drug therapy
researchProduct

Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more

2008

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …

Aminobisphosphonate Gamma delta T cells cancermedicine.medical_treatmentT cellClinical BiochemistryReceptors Antigen T-CellAntineoplastic AgentsModels BiologicalInterleukin 21Immune systemAntigenT-Lymphocyte SubsetsIn vivoNeoplasmsDrug DiscoveryAnimalsHumansCytotoxic T cellMedicinePharmacologyClinical Trials as TopicDiphosphonatesbusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaImmunotherapyKiller Cells Naturalmedicine.anatomical_structureImmune SystemImmunologyInterleukin-2ImmunotherapybusinessImmunologic MemoryExpert Opinion on Biological Therapy
researchProduct

The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists

2022

Abstract Purpose The prevention and early diagnosis of medication-related osteonecrosis of the jaw (MRONJ) is fundamental to reducing the incidence and progression of MRONJ. Many in the field believe that dental hygienists should play an integral role in primary and secondary MRONJ prevention. However, to date, very few publications in the literature have proposed standardised MRONJ protocols, which are dedicated to dental hygienists. The aim of this study was to provide guidance to the health care providers managing MRONJ. Methods The expert opinion in this study was developed by dental hygienists from the main Italian technical-scientific associations (Italian Dental Hygienists Associatio…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawRisk factorsOncologyDental hygienistsIncidencePreventionHumansDental hygienists; MRONJ; Osteonecrosis of the jaw; Periodontal screening score; Prevention; Risk factorsBisphosphonate-Associated Osteonecrosis of the JawPeriodontal screening scoreMRONJSupportive Care in Cancer
researchProduct

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evalu…

2022

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawZoledronic acid; Denosumab; Bone metastases; Solid cancer; Osteonecrosis of the jaw; MRONJCost-Benefit AnalysisBone metastasesSolid cancerPamidronateBone NeoplasmsMRONJRisk AssessmentOncologyQuality of LifeHumansBisphosphonate-Associated Osteonecrosis of the JawDenosumabZoledronic acid
researchProduct

Computed tomography bone density variations in oncological patients undergoing antiresorptive medication

2021

The purpose of this study was to compare jaw and cervical vertebrae bone density in computed tomography (CT) analyses of oncological patients undergoing antiresorptive medication with control patients, aiming to find information that may assist the radiologist and clinician in predicting risks and monitoring osteonecrosis in the jaw. Thirty-one patients treated with zoledronic acid and 37 control were included in the study. Two areas in regions of interest were chosen and standardized, one in the lower portion of the mandible and another in the axial cervical vertebra (C2) of patients undergoing antiresorptive drug treatment (experimental group) and the control group. Density analysis was p…

Bone Density Conservation AgentsDiphosphonatesReproducibility of Resultsmyofibromadesmoplastic fibromaOtorhinolaryngologynodular fasciitisBone DensityHumansmyofibroblastic sarcomaBisphosphonate-Associated Osteonecrosis of the JawSurgeryinflammatory myofibroblastic tumorTomography X-Ray ComputedGeneral DentistryUNESCO:CIENCIAS MÉDICAS
researchProduct

Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review

2015

Introduction: Orthodontic anchorage is one of the most challenging aspects of Orthodontics. Preventing undesired movement of teeth could result in safer and less complicated orthodontic treatment. Recently, several reviews have been published about the effects of different molecules on bone physiology and the clinical side effects in Orthodontics. However, the effects of local application of these substances on the rate of orthodontic tooth movement have not been assessed.Objectives: The aim of this research was to analyze the scientific evidence published in the literature about the effects of different molecules on orthodontic anchorage.Methods: The literature was systematically reviewed …

Bone remodeling periodBisfosfonatosTooth Movement TechniquesMovimentação dentáriaPharmacological managementAnti-Inflammatory AgentsOsteoclastsPamidronateDentistryZoledronic AcidAntioxidantsLactonesMiceStilbenesOrthodontic Anchorage ProceduresMedicineAgentes anti-inflamatóriosSulfonesAnti-inflammatory agentsOrthodonticsDiphosphonatesOsteoprotegerinaImidazolesOrthodontic anchorage proceduresArticlesBisphosphonatesProcedimentos de ancoragem ortodônticaTooth movementInclusion and exclusion criteriaBone RemodelingTooth MobilityOral SurgeryDiclofenacMEDLINEOrthodonticsKappa indexInterferon-gammaAnimalsHumansbusiness.industryOsteoprotegerinBone physiologyIsoxazolesOrthodontic Anchorage ProceduresAcetylcysteineRatslcsh:RK1-715CelecoxibResveratrolTooth movementlcsh:DentistryClodronic Acidbusiness
researchProduct